

Global iPSC-Derived Cell Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

<https://marketpublishers.com/r/G6CF0226553FEN.html>

Date: August 2026

Pages: 131

Price: US\$ 3,480.00 (Single User License)

ID: G6CF0226553FEN

Abstracts

According to our (Global Info Research) latest study, the global iPSC-Derived Cell Therapy market size was valued at US\$ 10711 million in 2025 and is forecast to a readjusted size of US\$ 22604 million by 2032 with a CAGR of 11.2% during review period.

iPSC-Derived Cell Therapy refers to living cell therapeutic products manufactured from induced pluripotent stem cells (iPSCs) through processes including directed differentiation, purification, expansion, genetic engineering, and quality release testing. These products encompass multiple cell types such as NK/T immune cells, neural progenitor cells, cardiomyocytes, pancreatic islet cells, retinal cells, and mesenchymal stromal cells. They are being developed for applications in oncology, Parkinson's disease, heart failure, diabetes, retinal degenerative diseases, and inflammatory tissue repair. The platform emphasizes lineage consistency, genomic stability, control of residual undifferentiated cells, immune matching strategies, cryopreserved formulation, and clinical-grade GMP scalable manufacturing capabilities. The overall gross margin is approximately 65%.

Demand for iPSC-derived cell therapies is primarily driven by high unmet clinical needs in refractory cancers, neurodegenerative disorders, heart failure, diabetes, and inherited retinal diseases. iPSCs provide a continuously expandable cell source, enabling a shift from donor-dependent therapies or patient-specific autologous manufacturing toward standardized, scalable, and potentially off-the-shelf cell products. This transition is gradually enabling batch production and inventory-based supply models in cell replacement therapy, immunotherapy, and tissue regeneration.

Product development is concentrated on allogeneic universal donor approaches, HLA-matched cell banks, low-immunogenicity gene-edited cell lines, CAR-iNK/CAR-iT platforms, iPSC-derived islet cells, neural progenitor cells, and cardiomyocyte-based therapies. Competitive differentiation is no longer limited to cell type selection, but increasingly depends on stable differentiation protocols, master cell bank quality, detection of residual undifferentiated cells, potency assays, post-thaw functional recovery, and closed-system GMP scale-up capabilities.

Regional opportunities are concentrated in the United States, Japan, China, and Europe. Japan maintains a first-mover advantage in regenerative medicine regulation and iPSC clinical translation, U.S. companies lead in immune cell engineering and financing strength, while Chinese companies are advancing rapidly in neurological disease clinical development. Key risks include tumorigenicity, immune rejection, long-term patient follow-up requirements, high manufacturing costs, and inconsistency in release standards. Companies capable of simultaneously addressing safety, scalability, and clinically validated efficacy are more likely to secure strategic partnerships and industry adoption.

Report Scope

This report is a detailed and comprehensive analysis for global iPSC-Derived Cell Therapy market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global iPSC-Derived Cell Therapy market size and forecasts, in consumption value (\$ Million), 2021-2032

Global iPSC-Derived Cell Therapy market size and forecasts by region and country, in consumption value (\$ Million), 2021-2032

Global iPSC-Derived Cell Therapy market size and forecasts, by Type and by Application, in consumption value (\$ Million), 2021-2032

Global iPSC-Derived Cell Therapy market shares of main players, in revenue (\$ Million), 2021-2026

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for iPSC-Derived Cell Therapy

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global iPSC-Derived Cell Therapy market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Fate Therapeutics, Century Therapeutics, Sumitomo Pharma, BlueRock Therapeutics, Heartseed, Sana Biotechnology, Aspen Neuroscience, iRegene Therapeutics, XellSmart, TreeFrog Therapeutics, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

iPSC-Derived Cell Therapy market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type

iPSC-Derived NK Cell Therapy

iPSC-Derived T Cell Therapy

iPSC-Derived Neural Cell Therapy

iPSC-Derived Cardiomyocyte Therapy

iPSC-Derived Pancreatic Islet Cell Therapy

iPSC-Derived Retinal Cell Therapy

iPSC-Derived Mesenchymal Stromal Cell Therapy

Other iPSC-Derived Cell Therapy

Market segment by Immune Matching Strategy

Standard Allogeneic Therapy

HLA-Matched Allogeneic Therapy

Gene-Edited Hypoimmune Therapy

Autologous Patient-Specific Therapy

Other Immune Matching Strategy

Market segment by Development Stage

Approved or Conditional Approval

Phase III or Pivotal Clinical

Phase II Clinical

Phase I or I/II Clinical

Preclinical or IND-Enabling

Discovery and Research

Market segment by Administration Site

Intravenous Systemic Delivery

Intracerebral or Putaminal Delivery

Intramyocardial Delivery

Subretinal or Ocular Delivery

Intra-Articular Delivery

Topical or Implantable Dressing

Other Local Delivery

Market segment by Application

Oncology

Neurological Disorders

Cardiovascular Diseases

Diabetes and Metabolic Diseases

Ophthalmic Diseases

Other Regenerative and Immune Diseases

Market segment by players, this report covers

Fate Therapeutics

Century Therapeutics

Sumitomo Pharma

BlueRock Therapeutics

Heartseed

Sana Biotechnology

Aspen Neuroscience

iRegene Therapeutics

XellSmart

TreeFrog Therapeutics

Cynata Therapeutics

Shoreline Biosciences

Evotec

FUJIFILM Cellular Dynamics

Opis Therapeutics

Cellistic

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

Chapter Outline

Chapter 1, to describe iPSC-Derived Cell Therapy product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of iPSC-Derived Cell Therapy, with revenue, gross margin, and global market share of iPSC-Derived Cell Therapy from 2021 to 2026.

Chapter 3, the iPSC-Derived Cell Therapy competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026. and iPSC-Derived Cell Therapy market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of iPSC-Derived Cell Therapy.

Chapter 13, to describe iPSC-Derived Cell Therapy research findings and conclusion.

Contents

1 MARKET OVERVIEW

1.1 Product Overview and Scope

1.2 Market Estimation Caveats and Base Year

1.3 Classification of iPSC-Derived Cell Therapy by Type

1.3.1 Overview: Global iPSC-Derived Cell Therapy Market Size by Type: 2021 Versus 2025 Versus 2032

1.3.2 Global iPSC-Derived Cell Therapy Consumption Value Market Share by Type in 2025

1.3.3 iPSC-Derived NK Cell Therapy

1.3.4 iPSC-Derived T Cell Therapy

1.3.5 iPSC-Derived Neural Cell Therapy

1.3.6 iPSC-Derived Cardiomyocyte Therapy

1.3.7 iPSC-Derived Pancreatic Islet Cell Therapy

1.3.8 iPSC-Derived Retinal Cell Therapy

1.3.9 iPSC-Derived Mesenchymal Stromal Cell Therapy

1.3.10 Other iPSC-Derived Cell Therapy

1.4 Classification of iPSC-Derived Cell Therapy by Immune Matching Strategy

1.4.1 Overview: Global iPSC-Derived Cell Therapy Market Size by Immune Matching Strategy: 2021 Versus 2025 Versus 2032

1.4.2 Global iPSC-Derived Cell Therapy Consumption Value Market Share by Immune Matching Strategy in 2025

1.4.3 Standard Allogeneic Therapy

1.4.4 HLA-Matched Allogeneic Therapy

1.4.5 Gene-Edited Hypoimmune Therapy

1.4.6 Autologous Patient-Specific Therapy

1.4.7 Other Immune Matching Strategy

1.5 Classification of iPSC-Derived Cell Therapy by Development Stage

1.5.1 Overview: Global iPSC-Derived Cell Therapy Market Size by Development Stage: 2021 Versus 2025 Versus 2032

1.5.2 Global iPSC-Derived Cell Therapy Consumption Value Market Share by Development Stage in 2025

1.5.3 Approved or Conditional Approval

1.5.4 Phase III or Pivotal Clinical

1.5.5 Phase II Clinical

1.5.6 Phase I or I/II Clinical

1.5.7 Preclinical or IND-Enabling

- 1.5.8 Discovery and Research
- 1.6 Classification of iPSC-Derived Cell Therapy by Administration Site
 - 1.6.1 Overview: Global iPSC-Derived Cell Therapy Market Size by Administration Site: 2021 Versus 2025 Versus 2032
 - 1.6.2 Global iPSC-Derived Cell Therapy Consumption Value Market Share by Administration Site in 2025
 - 1.6.3 Intravenous Systemic Delivery
 - 1.6.4 Intracerebral or Putaminal Delivery
 - 1.6.5 Intramyocardial Delivery
 - 1.6.6 Subretinal or Ocular Delivery
 - 1.6.7 Intra-Articular Delivery
 - 1.6.8 Topical or Implantable Dressing
 - 1.6.9 Other Local Delivery
- 1.7 Global iPSC-Derived Cell Therapy Market by Application
 - 1.7.1 Overview: Global iPSC-Derived Cell Therapy Market Size by Application: 2021 Versus 2025 Versus 2032
 - 1.7.2 Oncology
 - 1.7.3 Neurological Disorders
 - 1.7.4 Cardiovascular Diseases
 - 1.7.5 Diabetes and Metabolic Diseases
 - 1.7.6 Ophthalmic Diseases
 - 1.7.7 Other Regenerative and Immune Diseases
- 1.8 Global iPSC-Derived Cell Therapy Market Size & Forecast
- 1.9 Global iPSC-Derived Cell Therapy Market Size and Forecast by Region
 - 1.9.1 Global iPSC-Derived Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
 - 1.9.2 Global iPSC-Derived Cell Therapy Market Size by Region, (2021-2032)
 - 1.9.3 North America iPSC-Derived Cell Therapy Market Size and Prospect (2021-2032)
 - 1.9.4 Europe iPSC-Derived Cell Therapy Market Size and Prospect (2021-2032)
 - 1.9.5 Asia-Pacific iPSC-Derived Cell Therapy Market Size and Prospect (2021-2032)
 - 1.9.6 South America iPSC-Derived Cell Therapy Market Size and Prospect (2021-2032)
 - 1.9.7 Middle East & Africa iPSC-Derived Cell Therapy Market Size and Prospect (2021-2032)

2 COMPANY PROFILES

2.1 Fate Therapeutics

- 2.1.1 Fate Therapeutics Details
- 2.1.2 Fate Therapeutics Major Business
- 2.1.3 Fate Therapeutics iPSC-Derived Cell Therapy Product and Solutions
- 2.1.4 Fate Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
- 2.1.5 Fate Therapeutics Recent Developments and Future Plans
- 2.2 Century Therapeutics
 - 2.2.1 Century Therapeutics Details
 - 2.2.2 Century Therapeutics Major Business
 - 2.2.3 Century Therapeutics iPSC-Derived Cell Therapy Product and Solutions
 - 2.2.4 Century Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.2.5 Century Therapeutics Recent Developments and Future Plans
- 2.3 Sumitomo Pharma
 - 2.3.1 Sumitomo Pharma Details
 - 2.3.2 Sumitomo Pharma Major Business
 - 2.3.3 Sumitomo Pharma iPSC-Derived Cell Therapy Product and Solutions
 - 2.3.4 Sumitomo Pharma iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.3.5 Sumitomo Pharma Recent Developments and Future Plans
- 2.4 BlueRock Therapeutics
 - 2.4.1 BlueRock Therapeutics Details
 - 2.4.2 BlueRock Therapeutics Major Business
 - 2.4.3 BlueRock Therapeutics iPSC-Derived Cell Therapy Product and Solutions
 - 2.4.4 BlueRock Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.4.5 BlueRock Therapeutics Recent Developments and Future Plans
- 2.5 Heartseed
 - 2.5.1 Heartseed Details
 - 2.5.2 Heartseed Major Business
 - 2.5.3 Heartseed iPSC-Derived Cell Therapy Product and Solutions
 - 2.5.4 Heartseed iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.5.5 Heartseed Recent Developments and Future Plans
- 2.6 Sana Biotechnology
 - 2.6.1 Sana Biotechnology Details
 - 2.6.2 Sana Biotechnology Major Business
 - 2.6.3 Sana Biotechnology iPSC-Derived Cell Therapy Product and Solutions
 - 2.6.4 Sana Biotechnology iPSC-Derived Cell Therapy Revenue, Gross Margin and

Market Share (2021-2026)

2.6.5 Sana Biotechnology Recent Developments and Future Plans

2.7 Aspen Neuroscience

2.7.1 Aspen Neuroscience Details

2.7.2 Aspen Neuroscience Major Business

2.7.3 Aspen Neuroscience iPSC-Derived Cell Therapy Product and Solutions

2.7.4 Aspen Neuroscience iPSC-Derived Cell Therapy Revenue, Gross Margin and

Market Share (2021-2026)

2.7.5 Aspen Neuroscience Recent Developments and Future Plans

2.8 iRegene Therapeutics

2.8.1 iRegene Therapeutics Details

2.8.2 iRegene Therapeutics Major Business

2.8.3 iRegene Therapeutics iPSC-Derived Cell Therapy Product and Solutions

2.8.4 iRegene Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and

Market Share (2021-2026)

2.8.5 iRegene Therapeutics Recent Developments and Future Plans

2.9 XellSmart

2.9.1 XellSmart Details

2.9.2 XellSmart Major Business

2.9.3 XellSmart iPSC-Derived Cell Therapy Product and Solutions

2.9.4 XellSmart iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

2.9.5 XellSmart Recent Developments and Future Plans

2.10 TreeFrog Therapeutics

2.10.1 TreeFrog Therapeutics Details

2.10.2 TreeFrog Therapeutics Major Business

2.10.3 TreeFrog Therapeutics iPSC-Derived Cell Therapy Product and Solutions

2.10.4 TreeFrog Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

2.10.5 TreeFrog Therapeutics Recent Developments and Future Plans

2.11 Cynata Therapeutics

2.11.1 Cynata Therapeutics Details

2.11.2 Cynata Therapeutics Major Business

2.11.3 Cynata Therapeutics iPSC-Derived Cell Therapy Product and Solutions

2.11.4 Cynata Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)

2.11.5 Cynata Therapeutics Recent Developments and Future Plans

2.12 Shoreline Biosciences

2.12.1 Shoreline Biosciences Details

- 2.12.2 Shoreline Biosciences Major Business
- 2.12.3 Shoreline Biosciences iPSC-Derived Cell Therapy Product and Solutions
- 2.12.4 Shoreline Biosciences iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
- 2.12.5 Shoreline Biosciences Recent Developments and Future Plans
- 2.13 Evotec
 - 2.13.1 Evotec Details
 - 2.13.2 Evotec Major Business
 - 2.13.3 Evotec iPSC-Derived Cell Therapy Product and Solutions
 - 2.13.4 Evotec iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.13.5 Evotec Recent Developments and Future Plans
- 2.14 FUJIFILM Cellular Dynamics
 - 2.14.1 FUJIFILM Cellular Dynamics Details
 - 2.14.2 FUJIFILM Cellular Dynamics Major Business
 - 2.14.3 FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Product and Solutions
 - 2.14.4 FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.14.5 FUJIFILM Cellular Dynamics Recent Developments and Future Plans
- 2.15 Opsi Therapeutics
 - 2.15.1 Opsi Therapeutics Details
 - 2.15.2 Opsi Therapeutics Major Business
 - 2.15.3 Opsi Therapeutics iPSC-Derived Cell Therapy Product and Solutions
 - 2.15.4 Opsi Therapeutics iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.15.5 Opsi Therapeutics Recent Developments and Future Plans
- 2.16 Cellistic
 - 2.16.1 Cellistic Details
 - 2.16.2 Cellistic Major Business
 - 2.16.3 Cellistic iPSC-Derived Cell Therapy Product and Solutions
 - 2.16.4 Cellistic iPSC-Derived Cell Therapy Revenue, Gross Margin and Market Share (2021-2026)
 - 2.16.5 Cellistic Recent Developments and Future Plans

3 MARKET COMPETITION, BY PLAYERS

- 3.1 Global iPSC-Derived Cell Therapy Revenue and Share by Players (2021-2026)
- 3.2 Market Share Analysis (2025)
 - 3.2.1 Market Share of iPSC-Derived Cell Therapy by Company Revenue

- 3.2.2 Top 3 iPSC-Derived Cell Therapy Players Market Share in 2025
- 3.2.3 Top 6 iPSC-Derived Cell Therapy Players Market Share in 2025
- 3.3 iPSC-Derived Cell Therapy Market: Overall Company Footprint Analysis
 - 3.3.1 iPSC-Derived Cell Therapy Market: Region Footprint
 - 3.3.2 iPSC-Derived Cell Therapy Market: Company Product Type Footprint
 - 3.3.3 iPSC-Derived Cell Therapy Market: Company Product Application Footprint
- 3.4 New Market Entrants and Barriers to Market Entry
- 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 MARKET SIZE SEGMENT BY TYPE

- 4.1 Global iPSC-Derived Cell Therapy Consumption Value and Market Share by Type (2021-2026)
- 4.2 Global iPSC-Derived Cell Therapy Market Forecast by Type (2027-2032)

5 MARKET SIZE SEGMENT BY APPLICATION

- 5.1 Global iPSC-Derived Cell Therapy Consumption Value Market Share by Application (2021-2026)
- 5.2 Global iPSC-Derived Cell Therapy Market Forecast by Application (2027-2032)

6 NORTH AMERICA

- 6.1 North America iPSC-Derived Cell Therapy Consumption Value by Type (2021-2032)
- 6.2 North America iPSC-Derived Cell Therapy Market Size by Application (2021-2032)
- 6.3 North America iPSC-Derived Cell Therapy Market Size by Country
 - 6.3.1 North America iPSC-Derived Cell Therapy Consumption Value by Country (2021-2032)
 - 6.3.2 United States iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
 - 6.3.3 Canada iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
 - 6.3.4 Mexico iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

7 EUROPE

- 7.1 Europe iPSC-Derived Cell Therapy Consumption Value by Type (2021-2032)
- 7.2 Europe iPSC-Derived Cell Therapy Consumption Value by Application (2021-2032)
- 7.3 Europe iPSC-Derived Cell Therapy Market Size by Country
 - 7.3.1 Europe iPSC-Derived Cell Therapy Consumption Value by Country (2021-2032)
 - 7.3.2 Germany iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

- 7.3.3 France iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
- 7.3.4 United Kingdom iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
- 7.3.5 Russia iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
- 7.3.6 Italy iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

8 ASIA-PACIFIC

- 8.1 Asia-Pacific iPSC-Derived Cell Therapy Consumption Value by Type (2021-2032)
- 8.2 Asia-Pacific iPSC-Derived Cell Therapy Consumption Value by Application (2021-2032)
- 8.3 Asia-Pacific iPSC-Derived Cell Therapy Market Size by Region
 - 8.3.1 Asia-Pacific iPSC-Derived Cell Therapy Consumption Value by Region (2021-2032)
 - 8.3.2 China iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
 - 8.3.3 Japan iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
 - 8.3.4 South Korea iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
 - 8.3.5 India iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
 - 8.3.6 Southeast Asia iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
 - 8.3.7 Australia iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

9 SOUTH AMERICA

- 9.1 South America iPSC-Derived Cell Therapy Consumption Value by Type (2021-2032)
- 9.2 South America iPSC-Derived Cell Therapy Consumption Value by Application (2021-2032)
- 9.3 South America iPSC-Derived Cell Therapy Market Size by Country
 - 9.3.1 South America iPSC-Derived Cell Therapy Consumption Value by Country (2021-2032)
 - 9.3.2 Brazil iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)
 - 9.3.3 Argentina iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

10 MIDDLE EAST & AFRICA

- 10.1 Middle East & Africa iPSC-Derived Cell Therapy Consumption Value by Type (2021-2032)
- 10.2 Middle East & Africa iPSC-Derived Cell Therapy Consumption Value by

Application (2021-2032)

10.3 Middle East & Africa iPSC-Derived Cell Therapy Market Size by Country

10.3.1 Middle East & Africa iPSC-Derived Cell Therapy Consumption Value by Country (2021-2032)

10.3.2 Turkey iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

10.3.3 Saudi Arabia iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

10.3.4 UAE iPSC-Derived Cell Therapy Market Size and Forecast (2021-2032)

11 MARKET DYNAMICS

11.1 iPSC-Derived Cell Therapy Market Drivers

11.2 iPSC-Derived Cell Therapy Market Restraints

11.3 iPSC-Derived Cell Therapy Trends Analysis

11.4 Porters Five Forces Analysis

11.4.1 Threat of New Entrants

11.4.2 Bargaining Power of Suppliers

11.4.3 Bargaining Power of Buyers

11.4.4 Threat of Substitutes

11.4.5 Competitive Rivalry

12 INDUSTRY CHAIN ANALYSIS

12.1 iPSC-Derived Cell Therapy Industry Chain

12.2 iPSC-Derived Cell Therapy Upstream Analysis

12.3 iPSC-Derived Cell Therapy Midstream Analysis

12.4 iPSC-Derived Cell Therapy Downstream Analysis

13 RESEARCH FINDINGS AND CONCLUSION

14 APPENDIX

14.1 Methodology

14.2 Research Process and Data Source

14.3 Disclaimer

List Of Tables

LIST OF TABLES

Table 1. Global iPSC-Derived Cell Therapy Consumption Value by Type, (USD Million), 2021 & 2025 & 2032

Table 2. Global iPSC-Derived Cell Therapy Consumption Value by Immune Matching Strategy, (USD Million), 2021 & 2025 & 2032

Table 3. Global iPSC-Derived Cell Therapy Consumption Value by Development Stage, (USD Million), 2021 & 2025 & 2032

Table 4. Global iPSC-Derived Cell Therapy Consumption Value by Administration Site, (USD Million), 2021 & 2025 & 2032

Table 5. Global iPSC-Derived Cell Therapy Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Table 6. Global iPSC-Derived Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)

Table 7. Global iPSC-Derived Cell Therapy Consumption Value by Region (2027-2032) & (USD Million)

Table 8. Fate Therapeutics Company Information, Head Office, and Major Competitors

Table 9. Fate Therapeutics Major Business

Table 10. Fate Therapeutics iPSC-Derived Cell Therapy Product and Solutions

Table 11. Fate Therapeutics iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 12. Fate Therapeutics Recent Developments and Future Plans

Table 13. Century Therapeutics Company Information, Head Office, and Major Competitors

Table 14. Century Therapeutics Major Business

Table 15. Century Therapeutics iPSC-Derived Cell Therapy Product and Solutions

Table 16. Century Therapeutics iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 17. Century Therapeutics Recent Developments and Future Plans

Table 18. Sumitomo Pharma Company Information, Head Office, and Major Competitors

Table 19. Sumitomo Pharma Major Business

Table 20. Sumitomo Pharma iPSC-Derived Cell Therapy Product and Solutions

Table 21. Sumitomo Pharma iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 22. BlueRock Therapeutics Company Information, Head Office, and Major Competitors

Table 23. BlueRock Therapeutics Major Business
Table 24. BlueRock Therapeutics iPSC-Derived Cell Therapy Product and Solutions
Table 25. BlueRock Therapeutics iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 26. BlueRock Therapeutics Recent Developments and Future Plans
Table 27. Heartseed Company Information, Head Office, and Major Competitors
Table 28. Heartseed Major Business
Table 29. Heartseed iPSC-Derived Cell Therapy Product and Solutions
Table 30. Heartseed iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 31. Heartseed Recent Developments and Future Plans
Table 32. Sana Biotechnology Company Information, Head Office, and Major Competitors
Table 33. Sana Biotechnology Major Business
Table 34. Sana Biotechnology iPSC-Derived Cell Therapy Product and Solutions
Table 35. Sana Biotechnology iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 36. Sana Biotechnology Recent Developments and Future Plans
Table 37. Aspen Neuroscience Company Information, Head Office, and Major Competitors
Table 38. Aspen Neuroscience Major Business
Table 39. Aspen Neuroscience iPSC-Derived Cell Therapy Product and Solutions
Table 40. Aspen Neuroscience iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 41. Aspen Neuroscience Recent Developments and Future Plans
Table 42. iRegene Therapeutics Company Information, Head Office, and Major Competitors
Table 43. iRegene Therapeutics Major Business
Table 44. iRegene Therapeutics iPSC-Derived Cell Therapy Product and Solutions
Table 45. iRegene Therapeutics iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 46. iRegene Therapeutics Recent Developments and Future Plans
Table 47. XellSmart Company Information, Head Office, and Major Competitors
Table 48. XellSmart Major Business
Table 49. XellSmart iPSC-Derived Cell Therapy Product and Solutions
Table 50. XellSmart iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)
Table 51. XellSmart Recent Developments and Future Plans
Table 52. TreeFrog Therapeutics Company Information, Head Office, and Major

Competitors

Table 53. TreeFrog Therapeutics Major Business

Table 54. TreeFrog Therapeutics iPSC-Derived Cell Therapy Product and Solutions

Table 55. TreeFrog Therapeutics iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 56. TreeFrog Therapeutics Recent Developments and Future Plans

Table 57. Cynata Therapeutics Company Information, Head Office, and Major Competitors

Table 58. Cynata Therapeutics Major Business

Table 59. Cynata Therapeutics iPSC-Derived Cell Therapy Product and Solutions

Table 60. Cynata Therapeutics iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 61. Cynata Therapeutics Recent Developments and Future Plans

Table 62. Shoreline Biosciences Company Information, Head Office, and Major Competitors

Table 63. Shoreline Biosciences Major Business

Table 64. Shoreline Biosciences iPSC-Derived Cell Therapy Product and Solutions

Table 65. Shoreline Biosciences iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 66. Shoreline Biosciences Recent Developments and Future Plans

Table 67. Evotec Company Information, Head Office, and Major Competitors

Table 68. Evotec Major Business

Table 69. Evotec iPSC-Derived Cell Therapy Product and Solutions

Table 70. Evotec iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 71. Evotec Recent Developments and Future Plans

Table 72. FUJIFILM Cellular Dynamics Company Information, Head Office, and Major Competitors

Table 73. FUJIFILM Cellular Dynamics Major Business

Table 74. FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Product and Solutions

Table 75. FUJIFILM Cellular Dynamics iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 76. FUJIFILM Cellular Dynamics Recent Developments and Future Plans

Table 77. Opsi Therapeutics Company Information, Head Office, and Major Competitors

Table 78. Opsi Therapeutics Major Business

Table 79. Opsi Therapeutics iPSC-Derived Cell Therapy Product and Solutions

Table 80. Opsi Therapeutics iPSC-Derived Cell Therapy Revenue (USD Million),

Gross Margin and Market Share (2021-2026)

Table 81. Opsi Therapeutics Recent Developments and Future Plans

Table 82. Cellistic Company Information, Head Office, and Major Competitors

Table 83. Cellistic Major Business

Table 84. Cellistic iPSC-Derived Cell Therapy Product and Solutions

Table 85. Cellistic iPSC-Derived Cell Therapy Revenue (USD Million), Gross Margin and Market Share (2021-2026)

Table 86. Cellistic Recent Developments and Future Plans

Table 87. Global iPSC-Derived Cell Therapy Revenue (USD Million) by Players (2021-2026)

Table 88. Global iPSC-Derived Cell Therapy Revenue Share by Players (2021-2026)

Table 89. Breakdown of iPSC-Derived Cell Therapy by Company Type (Tier 1, Tier 2, and Tier 3)

Table 90. Market Position of Players in iPSC-Derived Cell Therapy, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2025

Table 91. Head Office of Key iPSC-Derived Cell Therapy Players

Table 92. iPSC-Derived Cell Therapy Market: Company Product Type Footprint

Table 93. iPSC-Derived Cell Therapy Market: Company Product Application Footprint

Table 94. iPSC-Derived Cell Therapy New Market Entrants and Barriers to Market Entry

Table 95. iPSC-Derived Cell Therapy Mergers, Acquisition, Agreements, and Collaborations

Table 96. Global iPSC-Derived Cell Therapy Consumption Value (USD Million) by Type (2021-2026)

Table 97. Global iPSC-Derived Cell Therapy Consumption Value Share by Type (2021-2026)

Table 98. Global iPSC-Derived Cell Therapy Consumption Value Forecast by Type (2027-2032)

Table 99. Global iPSC-Derived Cell Therapy Consumption Value by Application (2021-2026)

Table 100. Global iPSC-Derived Cell Therapy Consumption Value Forecast by Application (2027-2032)

Table 101. North America iPSC-Derived Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 102. North America iPSC-Derived Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 103. North America iPSC-Derived Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 104. North America iPSC-Derived Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 105. North America iPSC-Derived Cell Therapy Consumption Value by Country (2021-2026) & (USD Million)

Table 106. North America iPSC-Derived Cell Therapy Consumption Value by Country (2027-2032) & (USD Million)

Table 107. Europe iPSC-Derived Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 108. Europe iPSC-Derived Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 109. Europe iPSC-Derived Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 110. Europe iPSC-Derived Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 111. Europe iPSC-Derived Cell Therapy Consumption Value by Country (2021-2026) & (USD Million)

Table 112. Europe iPSC-Derived Cell Therapy Consumption Value by Country (2027-2032) & (USD Million)

Table 113. Asia-Pacific iPSC-Derived Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 114. Asia-Pacific iPSC-Derived Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 115. Asia-Pacific iPSC-Derived Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 116. Asia-Pacific iPSC-Derived Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 117. Asia-Pacific iPSC-Derived Cell Therapy Consumption Value by Region (2021-2026) & (USD Million)

Table 118. Asia-Pacific iPSC-Derived Cell Therapy Consumption Value by Region (2027-2032) & (USD Million)

Table 119. South America iPSC-Derived Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 120. South America iPSC-Derived Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 121. South America iPSC-Derived Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 122. South America iPSC-Derived Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 123. South America iPSC-Derived Cell Therapy Consumption Value by Country (2021-2026) & (USD Million)

Table 124. South America iPSC-Derived Cell Therapy Consumption Value by Country

(2027-2032) & (USD Million)

Table 125. Middle East & Africa iPSC-Derived Cell Therapy Consumption Value by Type (2021-2026) & (USD Million)

Table 126. Middle East & Africa iPSC-Derived Cell Therapy Consumption Value by Type (2027-2032) & (USD Million)

Table 127. Middle East & Africa iPSC-Derived Cell Therapy Consumption Value by Application (2021-2026) & (USD Million)

Table 128. Middle East & Africa iPSC-Derived Cell Therapy Consumption Value by Application (2027-2032) & (USD Million)

Table 129. Middle East & Africa iPSC-Derived Cell Therapy Consumption Value by Country (2021-2026) & (USD Million)

Table 130. Middle East & Africa iPSC-Derived Cell Therapy Consumption Value by Country (2027-2032) & (USD Million)

Table 131. Global Key Players of iPSC-Derived Cell Therapy Upstream (Raw Materials)

Table 132. Global iPSC-Derived Cell Therapy Typical Customers

List Of Figures

LIST OF FIGURES

- Figure 1. iPSC-Derived Cell Therapy Picture
- Figure 2. Global iPSC-Derived Cell Therapy Consumption Value by Type, (USD Million), 2021 & 2025 & 2032
- Figure 3. Global iPSC-Derived Cell Therapy Consumption Value Market Share by Type in 2025
- Figure 4. iPSC-Derived NK Cell Therapy
- Figure 5. iPSC-Derived T Cell Therapy
- Figure 6. iPSC-Derived Neural Cell Therapy
- Figure 7. iPSC-Derived Cardiomyocyte Therapy
- Figure 8. iPSC-Derived Pancreatic Islet Cell Therapy
- Figure 9. iPSC-Derived Retinal Cell Therapy
- Figure 10. iPSC-Derived Mesenchymal Stromal Cell Therapy
- Figure 11. Other iPSC-Derived Cell Therapy
- Figure 12. Global iPSC-Derived Cell Therapy Consumption Value by Immune Matching Strategy, (USD Million), 2021 & 2025 & 2032
- Figure 13. Global iPSC-Derived Cell Therapy Consumption Value Market Share by Immune Matching Strategy in 2025
- Figure 14. Standard Allogeneic Therapy
- Figure 15. HLA-Matched Allogeneic Therapy
- Figure 16. Gene-Edited Hypoimmune Therapy
- Figure 17. Autologous Patient-Specific Therapy
- Figure 18. Other Immune Matching Strategy
- Figure 19. Global iPSC-Derived Cell Therapy Consumption Value by Development Stage, (USD Million), 2021 & 2025 & 2032
- Figure 20. Global iPSC-Derived Cell Therapy Consumption Value Market Share by Development Stage in 2025
- Figure 21. Approved or Conditional Approval
- Figure 22. Phase III or Pivotal Clinical
- Figure 23. Phase II Clinical
- Figure 24. Phase I or I/II Clinical
- Figure 25. Preclinical or IND-Enabling
- Figure 26. Discovery and Research
- Figure 27. Global iPSC-Derived Cell Therapy Consumption Value by Administration Site, (USD Million), 2021 & 2025 & 2032
- Figure 28. Global iPSC-Derived Cell Therapy Consumption Value Market Share by

Administration Site in 2025

Figure 29. Intravenous Systemic Delivery

Figure 30. Intracerebral or Putaminal Delivery

Figure 31. Intramyocardial Delivery

Figure 32. Subretinal or Ocular Delivery

Figure 33. Intra-Articular Delivery

Figure 34. Topical or Implantable Dressing

Figure 35. Other Local Delivery

Figure 36. Global iPSC-Derived Cell Therapy Consumption Value by Application, (USD Million), 2021 & 2025 & 2032

Figure 37. iPSC-Derived Cell Therapy Consumption Value Market Share by Application in 2025

Figure 38. Oncology Picture

Figure 39. Neurological Disorders Picture

Figure 40. Cardiovascular Diseases Picture

Figure 41. Diabetes and Metabolic Diseases Picture

Figure 42. Ophthalmic Diseases Picture

Figure 43. Other Regenerative and Immune Diseases Picture

Figure 44. Global iPSC-Derived Cell Therapy Consumption Value, (USD Million): 2021 & 2025 & 2032

Figure 45. Global iPSC-Derived Cell Therapy Consumption Value and Forecast (2021-2032) & (USD Million)

Figure 46. Global Market iPSC-Derived Cell Therapy Consumption Value (USD Million) Comparison by Region (2021 VS 2025 VS 2032)

Figure 47. Global iPSC-Derived Cell Therapy Consumption Value Market Share by Region (2021-2032)

Figure 48. Global iPSC-Derived Cell Therapy Consumption Value Market Share by Region in 2025

Figure 49. North America iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 50. Europe iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 51. Asia-Pacific iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 52. South America iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 53. Middle East & Africa iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 54. Company Three Recent Developments and Future Plans

Figure 55. Global iPSC-Derived Cell Therapy Revenue Share by Players in 2025

Figure 56. iPSC-Derived Cell Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3) in 2025

Figure 57. Market Share of iPSC-Derived Cell Therapy by Player Revenue in 2025

Figure 58. Top 3 iPSC-Derived Cell Therapy Players Market Share in 2025

Figure 59. Top 6 iPSC-Derived Cell Therapy Players Market Share in 2025

Figure 60. Global iPSC-Derived Cell Therapy Consumption Value Share by Type (2021-2026)

Figure 61. Global iPSC-Derived Cell Therapy Market Share Forecast by Type (2027-2032)

Figure 62. Global iPSC-Derived Cell Therapy Consumption Value Share by Application (2021-2026)

Figure 63. Global iPSC-Derived Cell Therapy Market Share Forecast by Application (2027-2032)

Figure 64. North America iPSC-Derived Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 65. North America iPSC-Derived Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 66. North America iPSC-Derived Cell Therapy Consumption Value Market Share by Country (2021-2032)

Figure 67. United States iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 68. Canada iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 69. Mexico iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 70. Europe iPSC-Derived Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 71. Europe iPSC-Derived Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 72. Europe iPSC-Derived Cell Therapy Consumption Value Market Share by Country (2021-2032)

Figure 73. Germany iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 74. France iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 75. United Kingdom iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 76. Russia iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Million)

Figure 77. Italy iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 78. Asia-Pacific iPSC-Derived Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 79. Asia-Pacific iPSC-Derived Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 80. Asia-Pacific iPSC-Derived Cell Therapy Consumption Value Market Share by Region (2021-2032)

Figure 81. China iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 82. Japan iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 83. South Korea iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 84. India iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 85. Southeast Asia iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 86. Australia iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 87. South America iPSC-Derived Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 88. South America iPSC-Derived Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 89. South America iPSC-Derived Cell Therapy Consumption Value Market Share by Country (2021-2032)

Figure 90. Brazil iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 91. Argentina iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 92. Middle East & Africa iPSC-Derived Cell Therapy Consumption Value Market Share by Type (2021-2032)

Figure 93. Middle East & Africa iPSC-Derived Cell Therapy Consumption Value Market Share by Application (2021-2032)

Figure 94. Middle East & Africa iPSC-Derived Cell Therapy Consumption Value Market Share by Country (2021-2032)

Figure 95. Turkey iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 96. Saudi Arabia iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 97. UAE iPSC-Derived Cell Therapy Consumption Value (2021-2032) & (USD Million)

Figure 98. iPSC-Derived Cell Therapy Market Drivers

Figure 99. iPSC-Derived Cell Therapy Market Restraints

Figure 100. iPSC-Derived Cell Therapy Market Trends

Figure 101. Porters Five Forces Analysis

Figure 102. iPSC-Derived Cell Therapy Industrial Chain

Figure 103. Methodology

Figure 104. Research Process and Data Source

I would like to order

Product name: Global iPSC-Derived Cell Therapy Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Product link: <https://marketpublishers.com/r/G6CF0226553FEN.html>

Price: US\$ 3,480.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/G6CF0226553FEN.html>